Literature DB >> 18925855

Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead.

Katerina Malagari1.   

Abstract

The advantage of chemoembolization of the liver as an antineoplastic treatment for hepatocellular carcinoma is that it achieves high intratumoral concentrations of the chemotherapeutic agent locally that cannot be reached with systemic chemotherapy in nontoxic doses. However, chemotherapeutic release and local concentrations cannot be standardized by this technique. Drug-eluting beads have predictable pharmacokinetics and can achieve higher doses of the chemotherapeutic and prolonged contact time with cancer cells. The DC Bead is a drug-eluting bead that has proven favorable kinetics and clinical characteristics. This review describes the features of the DC Bead loaded with doxorubicin for the treatment of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925855     DOI: 10.1586/14737140.8.10.1643

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  15 in total

1.  Surgical and Locoregional Therapy of HCC: TACE.

Authors:  Masakatsu Tsurusaki; Takamichi Murakami
Journal:  Liver Cancer       Date:  2015-07-10       Impact factor: 11.740

Review 2.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 3.  HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.

Authors:  Thomas J Vogl; Tatjana Gruber-Rouh
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 4.  Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance.

Authors:  Andrew L Lewis; Sean L Willis; Matthew R Dreher; Yiqing Tang; Koorosh Ashrafi; Bradford J Wood; Elliot B Levy; Karun V Sharma; Ayele H Negussie; Andrew S Mikhail
Journal:  Future Oncol       Date:  2018-06-26       Impact factor: 3.404

Review 5.  New progress of non-surgical treatments for hepatocellular carcinoma.

Authors:  Ji-Wen Cheng; Yi Lv
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

6.  Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre.

Authors:  T Asmis; F Balaa; L Scully; D Papadatos; C Marginean; N Fasih; T Shaw-Stiffel; R Goel
Journal:  Curr Oncol       Date:  2010-04       Impact factor: 3.677

7.  Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol.

Authors:  Ming Yang; Samuel K Lai; Tao Yu; Ying-Ying Wang; Christina Happe; Weixi Zhong; Michael Zhang; Abraham Anonuevo; Colleen Fridley; Amy Hung; Jie Fu; Justin Hanes
Journal:  J Control Release       Date:  2014-07-29       Impact factor: 9.776

8.  Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment.

Authors:  Pi-Yi Chang; Chun-Chieh Huang; Chao-Hung Hung; Chih-Yung Yu; Ding-Kwo Wu; Jen-I Hwang; Po-Chin Liang; Reng-Hong Wu; Wei-Lun Tsai; Yih-Jyh Lin; Yi-Sheng Liu; Huei-Lung Liang; Rheun-Chuan Lee; Chien-Hung Chen
Journal:  Liver Cancer       Date:  2018-03-29       Impact factor: 11.740

Review 9.  Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides.

Authors:  Jean-Luc Raoul; Eveline Boucher; Yan Rolland; Etienne Garin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

10.  Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.

Authors:  Richard E J Forster; Sharon A Small; Yiqing Tang; Clare L Heaysman; Andrew W Lloyd; Wendy Macfarlane; Gary J Phillips; Milan D Antonijevic; Andrew L Lewis
Journal:  J Mater Sci Mater Med       Date:  2010-06-19       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.